The impact of HIV on clinical-microbiologic features and mortality among patients with invasive nontyphoidal Salmonella infection in South Africa by Mtandu, Rugola
THE IMPACT OF HIV ON CLINICAL-MICROBIOLOGIC 
FEATURES AND MORTALITY AMONG PATIENTS WITH 
INVASIVE NONTYPHOIDAL SALMONELLA INFECTION IN 
SOUTH AFRICA 
 
 
Rugola Mtandu 
 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of 
the Witwatersrand, in partial fulfilment of the requirements for the degree  
of  
Master of Science in Medicine in Epidemiology and Biostatistics 
 
 
Johannesburg, 2007 
 ii
DECLARATION 
I, Rugola Mtandu declare that this research report is my own work. It is being submitted 
for the degree of Master of Science in Medicine in the University of the Witwatersrand, 
Johannesburg. It has not been submitted before for any degree or examination at this or any 
other University. 
……………………. 
………………day of...…………….., 2007 
 iii
In memory of my late grandparents 
 Rugola, Bahitwa, Wabwiro and Wanyambarya Mkubwa 
 
 
 
 
Dedicated to my wife Irene and son Rugola Jr. 
 iv 
ABSTRACT 
Introduction: Nontyphoidal Salmonella (NTS) has been associated with HIV from the 
outset of the HIV pandemic. The few NTS studies done in Africa and America have not 
documented the impact of HIV on clinical-microbiologic features and mortality in patients 
with NTS infection. This study determined the association between HIV serostatus and 
mortality proportion, clinical presentation, length of hospital stay, frequency of invasive 
NTS infection recurrence, NTS serotypes and estimated the population attributable fraction 
of mortality due to HIV among patients with invasive NTS infection in South Africa. 
Methods: Secondary data from enteric diseases national surveillance in South Africa from 
2003 to 2006 were analysed as a cross sectional study. A total of 1 398 subjects with 
known HIV serostatus were obtained after data cleaning. Data analysis was done in Stata 
using chi squared test for categorical variables and Wilcoxon rank sum test / Kruskal-
Wallis test for continuous variables. Logistic regression models were used to quantify the 
associations, and adjust for confounders and effect modification. Population attributable 
fraction was calculated to quantify the impact of HIV on mortality.  
Results: Majority (82.26%) of patients were HIV positive. The frequency pattern of HIV 
positive serostatus in different age groups coincided with that of invasive NTS. The overall 
mortality was 32.00%. HIV positive patients had a higher proportion (35.79 %) of 
mortality than HIV negative patients (15.55 %) (P<0.001). Fifty five percent of deaths in 
this study population were attributed to HIV infection. In multivariate models, HIV 
positive patients were more likely than HIV negative patients to die (OR = 2.50, 95% CI 
1.69- 3.70), to develop lower respiratory tract infection (LRTI) (OR = 1.89, 95% CI,1.34-
2.65), to have recurrence of invasive NTS (OR = 3.90, 95% CI 1.41-10.77), to stay less 
than 16 days in hospitals (OR = 1.61, 95% CI, 1.08-2.40) and to be infected with 
Salmonella serotype Typhimurium infection (OR = 2.59, 95% CI 1.91-3.51). There were 
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no significant differences in temperature, cardiac arrest, meningitis and site of specimen 
isolation (p>0.05).  
Discussion: The major limitation to this study was poor data quality of the surveillance 
system, including missing HIV serostatus hence the findings cannot be generalized to 
patients with unknown HIV status.  
Conclusion: HIV infection is common among patients with invasive NTS and is 
associated with excess mortality, LRTI, fewer than 16 days of hospital stay, recurrent 
invasive NTS infection and Salmonella Typhimurium. It is important for clinicians to rule 
out HIV infection in patients with invasive NTS especially those presenting with LRTI and 
Salmonella Typhimurium infection in addition to recurrent NTS infection, which is a well-
known feature associated with HIV. 
Recommendation: Since these patients received antimicrobials and had considerable 
mortality, the first line treatment of invasive NTS should be reviewed especially to HIV 
positive patients by investigating resistance patterns and conducting a clinical trial of 
newer and effective antimicrobials. 
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CHAPTER 1 
1.0 INTRODUCTION 
Nontyphoidal Salmonella (NTS) infection is recognised as one of HIV opportunistic 
infections causing considerable morbidity and mortality, which has been given relatively 
little attention. The published literature on HIV and the associated clinical-microbiologic 
features and mortality of NTS infection is reviewed. The problem statement and the 
justification for the study are discussed herein. The chapter ends by stating the aim and 
objectives of the study. 
 
1.1 Overview of HIV opportunistic infections 
HIV infection is a risk factor for many if not virtually all infectious diseases (CDC, 1993b; 
Selik, et al., 1995; WHO, 2005). As our knowledge on HIV disease has continued to grow 
over the past 20 years, we have observed an increase in the frequency of infections 
associated with HIV disease, some unusual in the sense that they either had low prevalence 
or would naturally not cause infirmity in human beings in the pre-pandemic era (FAO, 
2004; Lange, et al., 2005; Levine, et al., 1991; Mfinanga, et al., 2004; Trevejo, et al., 
2005).  These infections have been given a name “opportunistic” which in simplistic terms 
means that they seize the “opportunity” of immunodeficiency state, primarily caused by 
HIV (UNAIDS, 1998). 
 
TB is one of the opportunistic infections which has had much attention and has been shown 
to be the leading cause of morbidity and mortality in HIV positive individuals worldwide 
and particularly in sub Saharan Africa where the burden of HIV-TB co infections is 
relatively heavy (Corbett, et al., 2003; Corbett, et al., 2006; Lange, et al., 2005; Range, et 
al., 2001; Wilkinson & Davies, 1997). Nevertheless other known opportunistic infections 
particularly of zoonotic nature which might also account for morbidity and mortality in 
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HIV positive patients have been given little attention (FAO, 2004; Mfinanga, et al., 2004). 
Amongst the zoonotic infections, invasive nontyphoidal Salmonella (NTS) infection has 
been known to be associated with HIV disease since the outset of the pandemic (Hohmann, 
2001; Levine, et al., 1991). This opportunistic infection is classified under clinical stage 4 
in WHO clinical staging for HIV/AIDS (WHO, 2005). 
 
Usually NTS infection is a self-limiting gastrointestinal infection in immunocompetent 
individuals (Chiu, et al., 2004; Gordon, et al., 2002). In immunocompromised conditions, 
in the very young and the elderly there is a high risk of NTS infection becoming invasive 
and eventually affecting a number of organs (Chiu, et al., 2004; Drinković, et al., 2004; 
Fraimow, et al., 1990; Hohmann, 2001; Kao, et al., 2005). Invasive NTS infection implies 
isolation of NTS from sites that are usually sterile, including blood, CSF, joint fluid, bone 
aspirate, pericardial fluid, pleural fluid, peritoneal fluid and deep-seated abscesses. 
 
1.2 LITERATURE REVIEW 
1.2.1 HIV as risk factor for NTS infection 
The advent of the HIV epidemic has changed the epidemiology of nontyphoidal 
Salmonella infection in human beings. A retrospective study conducted in the USA by 
Levine, et al., (1991) among men and women in states with high prevalence of AIDS, 
showed a substantial increase in the number of reported blood Salmonella isolates from 
1978 to 1987. The increase was most remarkable with Salmonella Enteritidis (Figure 1.1). 
Bacteraemia has been shown to be a common sequela of NTS infection in 
immunodeficiency states. Unpublished data from Massachusetts general hospital found 
that the common risk factors were corticosteroid use, malignancy and diabetes each at 15% 
level and HIV, previous use of antimicrobials and other immunosuppressive drugs each at 
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10% level. Extremes of age have also been identified to be a risk factor for NTS 
bacteraemia (Hohmann, 2001; Graham, et al., 2000b). 
 
In Africa, HIV infection is a major risk factor for NTS infections. Pithie, et al., (1993) in 
Zimbabwe found that NTS bacteraemia as compared to typhoid fever was strongly 
associated with HIV infection. In recent studies of HIV infected African adults with 
bacteraemia, NTS were isolated from 7% up to 37% of adults (Gordon, et al 2001; 
Hohmann, 2001; Holmes, et al., 2003). In general, bacterial infections were the second 
commonest OIs after TB whereby NTS was preceded by Streptococcus pneumoniae 
(Holmes, et al., 2003). 
 
Conversely, in a study of 100 adults with NTS bacteraemia in Malawi, HIV was confirmed 
by ELISA in 77 out of 78 tested giving a frequency of 99% (Gordon, et al., 2002). The 
importance of NTS bacteraemia associated morbidity and mortality in African countries 
where HIV is prevalent has also been elaborated (Gordon, et al., 2002; Graham, et al., 
2000a; Holmes, et al., 2003; Kankwatira, et al., 2004). 
 
1.2.2 Clinical Features of NTS infection 
The clinical presentation of NTS bacteraemia is non specific and usually NTS occurs with 
other infections. In children it usually presents as a febrile illness with no specific 
localizing signs (Graham, et al., 2000b). A number of studies have elaborated clinical 
presentation of NTS bacteraemia but failed to elicit the effect of HIV on clinical 
symptoms. In a Malawian study of 299 children aged from 0 to 14 years old with NTS 
bacteraemia and without focal sepsis, the common presenting symptoms were fever 
(96.6%), cough (66.7%) and diarrhoea (47.5%). Out of 264 children, clinical HIV infection 
was suspected using the WHO clinical case definition for childhood AIDS in 52 children 
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(19.7%) (Graham, et al., 2000a). Due to low sensitivity and specificity of WHO clinical 
case definition for AIDS (Osmond, 1998) many cases of HIV infection could have been 
missed in this study.  
 
Another study done in the same setting among 100 adults, found that the presenting 
symptoms were fever (90%), headache (60%), vomiting (51%), diarrhoea (46%), cough 
(45%), abdominal pain (36%), dyspnoea (31%), confusion (28%) and chest pain (27%). 
The median temperature and Glasgow coma score (GCS) were 39°C and 15 with ranges 
(35.3-41°C) and (3-15) respectively. (Gordon, et al., 2002). These two studies did not 
compare the clinical features between HIV positive and negative patients. 
 
Nevertheless in a study conducted in USA, among 60 adults with Salmonella enterica 
serotype Typhimurium, it was found that there was no significant difference of median 
duration of hospital stay between HIV positive and negative patients (Fisk, et al., 2005). 
These results could be due to the small sample size and possibly the high standard of care 
and access to health service resources in USA compared to the developing countries.  
 
Recurrence of NTS infection is also a common clinical feature. Two studies in Africa have 
associated NTS infection recurrence with HIV infection (Gordon, et al., 2002; Kankwatira, 
et al., 2004) but the effect of HIV in the recurrence was not elicited adequately due to 
inability of these studies to make a comparison between HIV positive and negative 
patients. 
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1.2.3 Microbiologic features of NTS infection 
The resistance to antimicrobials associated with NTS infection is well established 
(Hohmann, 2001; Gordon, et al., 2002; Graham, et al., 2000a; Fisk, et al., 2005; Walsh, et 
al., 2000). This study focused only on the distribution of NTS serotypes among HIV 
positive and negative patients. Most studies have shown Salmonella enterica serotype 
Enteriditis and serotype Typhimurium to be the common isolates in NTS bacteraemia 
(Gordon, et al., 2002; Graham, et al., 2000a; Hohmann, 2001; Levine, et al., 1991). The 
distribution between the two serotypes differs between Europe, USA and Africa. 
Surveillance data for salmonellosis in European union member states show that Salmonella 
Enteritidis is the predominant type (de Jong, et al., 2006). A study in Spain found that, 
Salmonella enterica serotype Enteritidis accounted for 70% and serotype Typhimurium 
accounted for 17% among 172 cases of Salmonella bacteraemia in 1982-1992 (Hohmann, 
2001) while in USA among culture confirmed Salmonella infection serotype Typhimurium 
was the most frequently identified and accounted for 27% of reported infections to CDC 
during 1996-1999 (Fisk, et al., 2005).  
 
In African NTS studies, Salmonella enterica serotype Typhimurium accounted for 75-79% 
and serotype Enteritidis accounted for 13-19% (Gordon, et al., 2002; Graham, et al., 
2000a). Gordon, et al., (2002) in Malawi further showed dual infections of Salmonella 
Typhimurium and Salmonella Enteritidis accounted for 1% and other Salmonella species 
accounted for 5% in adults with NTS bacteraemia. None of these studies have compared 
the prevalence of NTS serotypes between HIV positive and negative patients. 
Nevertheless, a recent study by Chierakul, et al., (2004) in Thailand showed that Group D 
nontyphoidal Salmonella bacteraemia, mainly Salmonella Enteritidis raised concurrent 
with the increase in HIV seroprevalence (Figure 1.2), replicating the findings by Levine, et 
al., (1991) (Figure 1.1). However the methodology employed in these two studies does not 
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provide evidence for a strong association between HIV infection and Salmonella 
Enteritidis. In South Africa the commonly isolated NTS serotypes in 2002/2003 were 
Salmonella Typhimurium (71.9%), Salmonella Enteritidis (8.8%) and Salmonella Isangi 
(6.3%) (Kruger, et al., 2004). 
 
Figure 1.1 Number of reported isolates of three Salmonella serotypes in states with high 
AIDS incidence, 1978-1987 in USA. 
(Source: Levine W.C., Buehler J.W., Bean N.H., et al., 1991. Epidemiology of 
nontyphoidal Salmonella bacteraemia during the human immunodeficiency virus epidemic. 
J Infect Dis., 164(1), 81-7) 
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I. 
Figure 1.2 (A) Incidence of bloodstream infections and HIV in Ubon Ratchatani, north-
eastern Thailand, during 1989 to 1998. (B) Changes in the incidence of HIV seropositivity, 
and HIV/AIDS in patients admitted to the regional hospital in Thailand. 
(Source: Chierakul W., Rajanuwong A., Wuthiekanun V. , et al., 2004. The changing 
pattern of bloodstream infections associated with the rise in HIV prevalence in north 
eastern Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 98, 
678—686) 
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1.2.4 Mortality associated with NTS infection 
The overall mortality rate associated with NTS bacteraemia is high. Studies conducted in 
Africa settings with high HIV prevalence show that it ranges from 24% in children 
(Graham, et al., 2000b) to 47% in adults (Gordon, et al., 2002). Two studies have 
compared mortality rates among HIV positive and negative patients with NTS bacteraemia 
but both have yielded conflicting results. A study by Graham, et al., (2000a) conducted 
among 299 Malawian children found that suspected HIV infection is associated with 
significantly higher mortality rate of 38.8% compared to mortality rate of 18.3% among 
children not suspected with HIV infection. Fisk, et al., (2005) in USA found that the 
mortality rate of 15% and 24% among HIV positive and negative NTS bacteraemic 
patients respectively was not statistically different. The failure to elicit the difference in the 
latter study could be due to small sample size of 60 patients. Nevertheless the lower 
median CD4 cell count of 39 cell/µl was associated with death in HIV patients. This 
finding has been supported by another study among a cohort of HIV infected patients 
which showed that the CD4 count below 50 cell/µl was strongly associated with risk of 
death (The PLATO Collaboration 2004). 
 
1.3 PROBLEM STATEMENT AND JUSTIFICATION 
South Africa is one of the worst affected countries in the world by the HIV pandemic 
(Steinbrook, 2004). By the end of 2005 the number of people infected with HIV was 
estimated to be 5.54 million and the prevalence of HIV in adults aged above 15 years was 
16.25% (Department of Health, Republic of South Africa, 2006). Recent estimates show 
that HIV is 11.2% in the general population (Dorrington, et al., 2006). The age group 
which bears the brunt of HIV attack is from 15 years to 64 years, with women being more 
affected in the age group 15 to 34 years while men are more affected above 35 years of age 
(Figure 1.3). The prevalence of NTS infections in South Africa is not known, but since it 
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has been established that HIV is a risk factor for invasive NTS infection (Thamlikitkul, et 
al., 1996; Fisk, et al., 2005) it can be presumed to be significant. There has been an 
increasing number of NTS isolates from 500 to 1500 in the year 1999 to 2003 at Enteric 
Diseases Reference Unit (EDRU) (Kruger, et al., 2004) and this could be reflecting the 
HIV epidemic in the country (Keddy, 2005). 
 
Information on the impact of HIV on invasive NTS infection has not been well 
documented in Africa and South Africa.  Most of the previous studies conducted in Africa, 
have used data from a single hospital, possibly resulting in sampling bias. Therefore in this 
study a 2003 to 2006 enhanced surveillance dataset of invasive NTS infection from the ten 
hospital sites (see Appendix I) was used. The dataset consists of approximately 1 398 
adults and paediatric patients with known HIV serostatus data, which were collected by 
surveillance officers. Information of patients with invasive NTS infection was extracted for 
analysis after data cleaning. By investigating the impact of HIV on clinical-microbiologic 
features and mortality in patients with invasive NTS infection, the study has provided 
evidence based information for the need to scale up the management of patients with 
invasive NTS in South Africa so as to avoid excess mortality.  
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Figure 1.3 HIV prevalence in South Africa by age and sex. 
(Source: Dorrington R.E., Johnson L.F., Bradshaw D., et al., 2006. The Demographic 
Impact of HIV/AIDS in South Africa. National and Provincial Indicators for 2006. Cape 
Town: Centre for Actuarial Research, South African Medical Research Council and 
Actuarial Society of South Africa) 
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1.4 RESEARCH QUESTION 
Does HIV status influence the clinical features, nontyphoidal Salmonella serotypes and 
mortality among patients with invasive nontyphoidal Salmonella infection in South Africa?  
 
1.5 STUDY AIM AND SPECIFIC OBJECTIVES 
1.5.1 Study aim: To determine the impact of HIV on clinical-microbiologic features and 
mortality among patients with invasive nontyphoidal Salmonella infection aged from birth 
and above admitted in hospitals at 10 surveillance sites in South Africa, 2003-2006. 
1.5.2 Specific objectives: 
i) To describe socio-demographic characteristics and HIV status of patients with 
invasive NTS  
ii) To determine the distribution and use of ARVs, antimicrobials, mean CD4 
counts and median viral loads among HIV positive patients with invasive NTS 
according to age groups, gender and year of surveillance 
iii) To determine immunosuppressive conditions and antimicrobial use in HIV 
negative patients with invasive NTS according to age groups, gender and year 
of surveillance 
iv) To determine the association between HIV serostatus and mortality proportion, 
clinical presentation, length of hospital stay, frequency of invasive NTS 
infection recurrence, site of NTS isolation, number of previous admissions, 
NTS serotypes, mixed serotypes and mixed infections 
v) To estimate the population attributable fraction of mortality due to HIV among 
patients with invasive NTS 
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CHAPTER 2 
2.0 METHODS 
This chapter describes the methods used in the study, which include the study design, study 
population, sampling strategy, data source, methods for measuring variables, data 
management and ethical issues. 
 
2.1 Study Design 
This study was an analytical cross sectional study on the impact of HIV on clinical-
microbiologic features and mortality associated with invasive NTS infection. The study 
utilised data from the Enteric Diseases Enhanced National Surveillance database in South 
Africa. 
 
2.2 Study population 
The study population comprised of patients with a laboratory confirmed diagnosis of 
invasive NTS infection aged from birth to 92 years admitted to ten hospital surveillance 
sites from 2003 to 2006 in South Africa. These patients were interviewed by surveillance 
officers after taking informed consent. 
 
2.3 Sampling strategy 
All surveillance subjects from 2003-2006 with confirmed laboratory diagnosis of invasive 
NTS infection from enhanced surveillance sites were included in the study based on the 
following criteria:  
 
2.3.1 Inclusion criteria 
Patients aged from one day and above.  
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2.3.2 Exclusion criteria 
Patients with missing HIV serostatus. This variable was considered crucial for the study to 
be pertinent.  Patients with missing final outcome were not excluded because its absence 
was independent of clinical-microbiologic features. 
 
2.3.3 Sample size 
The 2003-2006 dataset contains 1 350 subjects with complete HIV and final outcome 
information on the discharge date. About 1 112 and 238 patients are HIV positive and 
negative, respectively. Taking into consideration 36% and 16% mortality proportion in the 
two groups, the sample size gives a power of 100% with an alpha of 0.05 using a two-sided 
test, (Stata, version 9). 
 
2.4 Data source 
Data collected by Enteric Diseases Reference unit (EDRU) for surveillance purposes was 
used for analysis. The EDRU is the unit of the National Institute for Communicable 
Diseases (NICD) that mainly deals with enteric diseases. It has been conducting hospital 
and laboratory based surveillance in 10 sentinel sites from 2000 to date, representing 
almost all provinces in the country. The following variables were extracted from the 2003-
2006 dataset which is relatively more comprehensive. 
 
2.4.1 Exposure variable 
HIV serostatus was confirmed by standard ELISA method at the surveillance sites and the 
EDRU laboratory. 
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2.4.2 Outcome variables 
2.4.2.1 Primary outcome 
Mortality: The mortality proportion between the two groups was measured and compared. 
Information on mortality was collected by surveillance officers who followed up the 
patients and recorded the final outcome at the admission hospital or referral hospital if the 
patient was referred. 
 
2.4.2.2 Secondary outcomes 
Clinical features 
Clinical features were recorded by surveillance officers from clinical notes of admitted 
patients. These were then filled in case report files (CRFs) (Appendix II). The information 
used for the purpose of this study included (a) Type of disease caused by invasive NTS 
infection (b) Body temperature, blood pressure, cardiac arrest, mental status and Glasgow 
Coma Score (c) Length of hospital stay (d) Frequency of invasive NTS infection 
recurrence (e) Site of NTS isolation (f) Number of previous admissions. The information 
on clinical features was generated by physicians who managed patients with invasive NTS 
infection.  
Number of previous admissions was obtained from the clinical history. Length of hospital 
stay was deduced from date of admission and date of final outcome, obtained from clinical 
history and discharge notes respectively. Body temperature, blood pressure, cardiac arrest, 
mental status and Glasgow Coma Score were obtained from physical examination notes. 
The first two variables were measured by thermometers and sphygmomanometers, 
respectively while the last three were assessed by standardized clinical criteria. Cardiac 
arrest was recorded to be present if the blood pressure was unrecordable or peripheral 
pulses were impalpable. Mental status was recorded as alert, disorientated, stuporous, 
comatose or unknown. Glasgow Coma Score was assessed by giving a score of 1 to 4 for 
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best eye response, 1 to 5 for best verbal response and 1 to 6 for best motor response with 
the total score ranging from 3 to 15.  Type of disease caused by invasive NTS infection 
was decided by the physicians following clinical history and physical examination 
findings. Site of NTS isolation was obtained from laboratory result forms positive for NTS. 
This information was provided by physicians who took the specimen for microbiology 
investigation. Other clinical features such as antimicrobial use and immunosuppressive 
conditions were considered as potential confounders. Immunosuppressive conditions 
included steroid therapy, chemotherapy, radiation, malignancy, diabetes mellitus, chronic 
renal failure, nephrotic syndrome, liver cirrhosis, kwashiorkor, marasmus, sickle cell 
anaemia, smoking, TB, PCP and excessive alcohol use.  
 
Microbiologic feature(s) 
Salmonella isolates from normally sterile sites were identified by participating laboratories 
according to the standard operating procedures of the NHLS and referred to EDRU. 
Microbiologic features were measured by differences in proportions of NTS serotypes, 
mixed serotypes and mixed infections in the two comparison groups. NTS serotyping was 
done at EDRU using standard operating techniques following the Kaufmann-White scheme 
(Brenner and McWhorter-Murlin, 1998) on isolates referred by participating laboratories 
and results kept in laboratory forms and registers. These results were linked to CRFs for 
the purpose of determining the relationship between HIV serostatus and NTS serotypes. 
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2.5 Data management and analysis  
2.5.1 Data cleaning 
The 2003 to 2006 datasets that are in Epi-Info 6.04c format were exported independently to 
Microsoft excel in which age, dates of birth, admission and specimen collection were 
checked and cleaned by use of formula and data validation feature of the program. Age was 
checked by finding the difference between date of birth and date of admission and was 
restricted between 0 to 100 years. In order to complement and verify the work done in 
Excel, the datasets were then transferred to Stata, where duplicate entries and unusual 
values for age and clinical parameters were identified and cleaned. Duplicate entries were 
considered in patients with the same type of Salmonella isolate who were recorded more 
than once within three weeks.  Patients who were admitted more than once outside the 
range of three weeks were assigned a new variable of recurrence and double counting in 
the analysis was avoided by assigning the same unique identifier. Missing information was 
also identified by use of Stata and a retrieval attempt was done by counterchecking the 
CRFs and communicating with the surveillance sites.  
 
2.5.1.2  Data appending 
The 2003 to 2006 clean datasets were then appended in Stata and a secondary variable 
“data” was added for identification of the year of the data in the combined dataset. 
 
2.5.1.3  Data extraction 
All  variables for the study were extracted from the combined dataset. 
 
2.5.1.4  Data coding 
Coding was done in Stata whereby categories and secondary variables were generated in 
order to facilitate data analysis. 
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2.5.2 Statistical methods 
2.5.2.1 Descriptive statistics 
The frequency distribution of HIV serostatus was calculated according to socio-
demographic characteristics such as age groups, gender, hospital status, province and year 
of surveillance. Use of ARVs, antimicrobial use, immunosuppressive conditions, mean 
CD4 counts and median viral loads for HIV positive patients were calculated according to 
age groups, gender and year of surveillance. Age groups were categorised in accordance 
with published literature on nontyphoidal Salmonella infections (Vugia, et al., 2004) which 
also overlaps with age groups described in  HIV/AIDS National and Provincial Indicators 
for 2006 (Dorrington, et al., 2006).  In addition immunosuppressive conditions and 
antimicrobial use associated with HIV negative patients were described using frequency 
distributions according to age groups and gender. Barcharts and tables for categorical and 
continuous variables were used accordingly. 
 
2.5.2.2  Analytical statistics 
Continuous variables 
Differences in means/medians for continuous variables like age and length of hospital stay 
between HIV positive and negative patients; and differences in mean CD4 counts and 
median viral loads according to age groups, gender and year of surveillance among HIV 
positive patients were calculated and analysed using Wilcoxon rank sum test in case of two 
comparison groups or Kruskal-Wallis test in case of more than two groups due to the 
skewed distribution of these variables.  
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Nominal variables 
Proportions for nominal variables like mortality proportion, clinical diagnosis, mental 
status, NTS serotypes between HIV positive and negative patients were calculated and 
analysed by chi squared test to find out the differences between these two comparison 
groups.  
 
Associations and Control for confounders 
In order to ascertain the association of HIV and clinical-microbiological features and 
mortality, odds ratios were calculated by logistic regression models. Univariate models 
were constructed to screen for significant associations at 10% level for HIV serostatus, 
clinical-microbiologic features and mortality. Significant associations were then adjusted 
for age, gender, province, hospital status (academic vs. non academic) antimicrobial usage, 
immunosuppressive conditions and type of diagnosis in multivariate models. Two final 
multivariate models (one without interaction terms and the other with interaction) were 
selected for each outcome depending on significance of predictor variables at 5% level, 
except in case of insignificant interaction whereby only one model was selected. All 
models have p<0.001 for likelihood ratio statistic and p>0.05 for Hosmer-Lemeshow 
goodness of fit test. 
 
Measures of impact 
The population attributable fraction (PAF) formula (Levin, 1953) was used to estimate the 
impact of HIV on mortality among patients with invasive NTS infection as shown below: 
PAF = p (OR-1)/p (OR-1) + 1  
where by p is the proportion of HIV positive serostatus among patients with NTS infection.  
OR is odds ratio for mortality in HIV positive patients with invasive NTS infection. 
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2.6 Ethical clearance 
University of the Witwatersrand Committee for Research on Human Subjects approved the 
study (Protocol number M060916) on 29
th
 September 2006. Permission to use the dataset 
was granted by the National Institute for Communicable Diseases. 
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CHAPTER 3 
3.0 RESULTS 
This chapter elaborates the socio-demographic characteristics of the study population, 
comparison of HIV serostatus by socio-demographic characteristics, analytical statistics 
and measure of impact of HIV on mortality among patients with NTS infection. 
 
3.1 Socio-demographic characteristics and HIV serostatus 
A total of  2 345 patients with invasive NTS were admitted between 2003 and 2006, among 
them 947 had unknown HIV status. These were excluded from the study and therefore the 
following findings cannot be generalized to the unknown HIV status group. An additional 
48 patients were excluded in the analysis of HIV and mortality due to missing information 
on final outcome at the hospitals (figure 3.1). Table 3.1 shows socio-demographic 
characteristics of 1 398 patients with known HIV status. Most patients (27.25%) were aged 
between 30-39 years, followed by under one year of age (17.38%) and the smallest number 
(1.80%) were in the age group 15-19 years. There was no gender difference; both males 
and females contributed approximately 50% each to the study population. Academic 
hospitals admitted more patients (88.41%) than non academic hospitals (11.59%). Gauteng 
and Mpumalanga provinces had, respectively, the highest proportion (73.89%) and lowest 
proportion (0.79%) of patients. Most of the admitted patients (28.47%) were in the year 
2005. The prevalence of HIV in the study population was considerably higher (82.26%) 
than that of the general population. The proportion of HIV positive serostatus was highest 
(95%) in the 20-29 and 30-39 years age group and lowest (30%) in the 10-14 years age 
group. HIV frequency peaked in under one year age group and declined up to 19 years, it 
then peaked again from 20 to 49 years and finally declined in 50 years and above (Chi 
squared test for trend = 117.42, p < 0.001). This pattern coincided with the frequency of 
invasive NTS in the same age groups (Figure 3.2).
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*Number exceeds the total number due to repeated observations. 
Figure 3.1 Flow chart of study subjects. 
 
All patients 
n = 2 345 
Known HIV status 
n = 1 398 
Unknown HIV status 
(Excluded from the 
study) 
n = 947 
HIV positive 
n = 1 150 
HIV negative 
n = 248 
HIV positive 
n = 1 112 
HIV negative 
n = 238 
 
Final outcome 
n = 1 350 
 
Missing final outcome 
n = 48 
Clinical-microbiologic features: 
Temperature, n = 201 
BP, n = 144 
Cardiac arrest, n = 192 
Mental status, n = 174 
Diagnosis, n = 246 
Length of hospital stay, n = 167 
*Recurrence, n = 253 
Specimen site, n =248 
Serotypes, n = 219 
 
Clinical-microbiologic features: 
Temperature, n = 841 
BP, n = 738 
Cardiac arrest, n = 769 
Mental status, n = 779 
Diagnosis, n = 1 137 
Length of hospital stay, n = 774 
*Recurrence, n = 1 230 
Specimen site, n= 1 150 
Serotypes, n = 1 074 
 
No. of previous admissions & GCS 
excluded due to >50% missing 
observations; mixed serotypes & mixed 
infections excluded due to n < 6 
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Table 3.1 Distribution of patients with invasive NTS infection by socio-demographic 
characteristics and HIV serostatus  
Characteristics 
 
Frequency Percentage 
Age groups (years) 
(n=1 387) 
  
  <1 241 17.38 
  1-4 107 7.71 
  5-9 63 4.54 
  10-14 33 2.38 
  15-19 25 1.80 
  20-29 214 15.43 
  30-39 378 27.25 
  40-49 220 15.86 
  50-59 74 5.34 
  60+ 32 2.31 
Gender (n=1 371)   
  Male 687 50.11 
  Female 684 49.89 
Hospital (n = 1 398)   
  Academic* 1 236 88.41 
  Non academic** 162 11.59 
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Table 3.1 continued 
Characteristics 
 
Frequency Percentage 
Province (n = 1 398)   
  Eastern Cape 56 4.01 
  Free State 51 3.65 
  Gauteng 1 033 73.89 
  Kwa Zulu Natal 112 8.01 
  Limpopo 18 1.29 
  Mpumalanga 11 0.79 
  Western Cape 117 8.37 
Year (n = 1 398)   
  2003 282 20.17 
  2004 375 26.82 
  2005 398 28.47 
  2006 343 24.54 
HIV status (n = 1 398)   
  Positive 1 150 82.26 
  Negative 248 17.74 
Note that n is not the same throughout, due to missing data in some categories. 
*Includes Addington, Baragwanath, Garankuwa, Groote Schuur, Johannesburg, King 
Edward, Red Cross, Tswane, Tygerberg, Universitas. 
**Includes Karl Bremer, Knobel, Mankweng, Pelonomi, Polokwane, Prince Mshiyeni, 
Public hospital Limpopo, R K Khan, Rob Ferreira, Standerton, Themba, Umtata, Victoria 
Western Cape. 
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Figure 3.2 Frequency of invasive NTS and (percentage) of HIV positive patients according 
to age groups. 
 
3.2 Distribution of HIV serostatus by socio-demographic characteristics  
HIV positive patients were significantly older than HIV negative. Mean age of HIV 
positive patients was 28 years old while that of HIV negative patients was 17 years old     
(p <0.001). Most HIV positive patients (31.58%) were aged between 30 and 39 years while 
most HIV negative patients (31.58%) were below one year of age. There was no statistical 
difference (p>0.05) between HIV positive and negative patients in gender. A significant 
difference (p<0.001) was observed in hospital admissions whereby more HIV positive 
patients (91.39%) were admitted in academic hospitals than HIV negative patients 
(74.60%). Most HIV positive (80.70%) and HIV negative patients (42.34%) came from 
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Gauteng province. There were no statistical differences between HIV positive and negative 
patients by the years of surveillance (P>0.05) (Table 3.2). 
 
Table 3.2 Distribution of HIV serostatus of patients with invasive NTS infection by socio - 
demographic characteristics  
HIV status Characteristics 
 
Positive 
%(n) 
Negative  
%(n) 
P-value* 
Age groups
 
(years)   
(n = 1 387) 
  0.0001 
Mean ± SD (Range) 27.62 ±  17.26 (0-87) 16.93 ± 21.09 (0-83) 0.0001** 
<1 14.30(163) 31.58 (78)  
1-4 6.49 (74) 9.31 (23)  
5-9 3.51 (40)  9.31 (23)  
10-14 0.88 (10) 9.31 (23)  
15-19 0.88 (10) 6.07 (15)  
20-29 17.89 (204) 4.05 (10)  
30-39 31.58 (360) 7.29 (18)  
40-49 17.63 (201) 7.69(19)  
50-59 5.09 (58) 6.48 (16)  
60+ 1.75 (20) 4.86 (12)  
Gender (n = 1 371)   0.242 
  Male 49.38 (558) 53.53 (129)  
  Female 50.62 (572) 46.47 (112)  
Hospital (n = 1 398)   0.0001 
  Academic 91.39 (1 051) 74.60 (185)  
  Non academic 8.61 (99) 25.40 (63)  
* P-value based on Pearson chi squared test unless otherwise stated. 
** P-value based on Wilcoxon rank sum test. 
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Table 3.2 continued 
HIV status Characteristics 
 
Positive 
%(n) 
Negative  
%(n) 
P-value* 
Province (n=1 398)   0.0001
¶
 
  Eastern Cape 2.26 (26) 12.10 (30)  
  Free State 2.61 (30) 8.47 (21)  
  Gauteng 80.70(928) 42.34 (105)  
  Kwa Zulu Natal 7.22 (83) 11.69 (29)  
  Limpopo 0.87 (10) 3.23 (8)  
  Mpumalanga 0.61 (7) 1.61 (4)  
  Western Cape 5.74 (66) 20.56 (51)  
Year (n=1 398)   0.190 
  2003 21.22 (244) 15.32 (38)  
  2004 26.35 (303) 29.03 (72)  
  2005 27.91 (321) 31.05 (77)  
  2006 24.52 (282) 24.60 (61)  
*P- value based on Pearson chi squared test unless otherwise stated. 
¶
P-value based on Fisher’s exact test. 
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3.3 Distribution and use of ARVs, antimicrobials and immunosuppressive 
conditions  
The differences in use of ARVs related to age were statistically significant (p <0.001). 
Table 3.3 shows that among HIV positive patients, those aged below one year had the 
highest proportion (16.11%) of ARV use. The age group 1-9 years had the second highest 
proportion (13.04%) of ARV use. The lowest ARV use (2.74%) was in patients aged 50 
years and above. The statistically significant difference (p<0.05) in use of ARVs was also 
found in gender and year of surveillance. In gender, males had a higher proportion 
(10.38%) of use of ARVs while in years there was an increasing trend from 6.19% in 2003 
to 13.6% in 2006. Generally, ARVs usage was low (8.44%) compared to the national 
estimate of 28%.  
There were no statistical significant differences in antimicrobial use by age groups and 
gender (p>0.05). More antimicrobials (99.25%) were used in the year 2006 compared to 
other years (p<0.001). 
In HIV negative patients there were no statistically significant differences (p>0.05) in 
immunosuppressive conditions by age groups and gender. In age groups, the average 
proportion of immunosuppressive conditions was 55%. In the year 2005, there was the 
highest proportion (81.82%) of immunosuppressive conditions that was statistically 
different (p<0.001) from other years. The year 2005 and 2006 had more than 50% of 
immunosuppressive conditions and the inverse was true for year 2003 and 2004. There 
were no statistically significant differences (p>0.05) in antimicrobial use by age groups and 
gender. The year 2006 had the highest proportion (100%) of antimicrobial use that was 
statistically different (p<0.001) from other years. 
In general, more HIV positive patients (90.64%) used antimicrobials than HIV negative 
patients (85.77%) and the difference was statistically significant (p<0.05). 
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Table 3.3 Distribution and use of ARVs, antimicrobials in HIV positive patients and  
immunosuppressive conditions, antimicrobial use in HIV negative patients by age groups, 
gender and year of surveillance 
Age groups (except <1) have been combined due to less than 5 expected observations  
ABX, Antimicrobial use. 
* Use of ARVs: Fisher’s exact test = 0.0001 for age groups; Pearson chi squared = 5.52, p 
= 0.019 for gender; Pearson chi squared = 11.01, p = 0.012 for year. 
** ABX use in HIV positive: Pearson chi squared = 8.89, p = 0.064 for age groups; 
Pearson chi squared = 0.08, p = 0.780 for gender; Pearson chi squared =311.33, p = 0.0001 
for year. 
¶ 
ABX use in HIV negative: Pearson chi squared = 1.11, p = 0.893 for age groups; Pearson 
chi squared = 0.04, p = 0.952 for gender; Pearson chi squared = 164.14, p = 0.0001 for 
year. 
+ 
ABX use in HIV positive and negative patients: Pearson chi squared =   5.05, p = 0.025. 
§
Immunosuppressive conditions, Pearson chi squared = 7.42, p = 0.115 for age groups; 
Pearson chi squared = 2.42, p = 0.119 for gender; Pearson chi squared = 41.31, p = 0.0001 
for year. 
HIV +  %(n/N) HIV - %(n/N) 
ARV use*%(n) ABX 
use**%(n) 
 
Immuno
§ 
%(n)
 
 
ABX 
use
¶
%(n)
 
Age 
groups 
(years)   
Yes No Yes Yes No Yes 
<1 16.11 (29) 83.89 (151) 88.54 (139) 43.59 (34) 56.41 (44) 84.00 (63) 
1-9 13.04 (18) 86.96 (120) 95.54 (107) 57.14 (32) 42.86 (24) 89.09 (49) 
10-29 3.08 (6) 96.92 (189) 87.38 (187) 47.92 (23) 52.08 (25) 87.50 (42) 
30-49 7.09 (27) 92.91 (354) 90.71 (488) 54.05 (20) 45.95 (17) 82.86 (29) 
50+ 2.74 (2) 97.26 (71) 95.83 (69) 71.43 (20) 28.57 (8) 84.00 (21) 
Gender        
Male 10.38 (49) 89.62 (423) 90.82 (485) 57.36 (74) 42.64 (55) 85.60 (107) 
Female 6.20 (30) 93.80 (454) 90.33 (495) 47.32 (53) 52.68 (59) 85.32 (93) 
Year       
2003 6.19 (12) 93.81 (182) 60.18 (136) 31.58 (12) 68.42 (26) 12.50 (4) 
2004 6.18 (17) 93.82 (258) 98.65 (293) 37.50 (27) 62.50 (45) 92.96 (66) 
2005 8.00 (22) 92.00 (253) 97.76 (305) 81.82 (63) 18.18 (14) 98.68 (75) 
2006 13.60 (31) 86.40 (197) 99.25 (263) 55.74 (34) 44.26 (27) 100.00 (60) 
Total
+
 8.44 (82) 91.56 (890) 90.64 (997) 52.02  (129) 47.98 (119)  85.77 (205) 
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3.3.1 Distribution of mean CD4 counts and median viral loads in HIV positive  
patients 
There was a decrease in mean CD4 count as age increased (Table 3.4). The differences of 
CD4 counts by age groups were statistically significant (p<0.001). The differences in CD4 
counts by gender and year of surveillance were not statistically significant (P>0.05). 
Differences in viral loads by age groups and gender were not statistically significant 
(P>0.05) except for year of surveillance (p<0.001). Due to more than 50% missing 
observations these results should be cautiously considered. The number of HIV positive 
patients with available respective CD4 counts and viral loads were 565 and 102. This 
differential missing may explain the unexpected finding of insignificant differences in viral 
loads by age groups. 
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Table 3.4 Distribution of CD4 counts and viral loads in HIV positive patients with 
invasive NTS infection by age groups, gender and year of surveillance 
Laboratory parameter  
CD4 count  
(mean ± SD, median) 
Mean Viral load 
(mean ± SD, median) 
Age groups* (years)   
<1 391 ±  382, 345 150591 ± 177180, 100000 
1-4 549 ± 604, 464 139667 ± 202398, 23000 
5-9 111 ± 111, 51 343667 ± 351569, 265000 
10-14 147.17 ± 112.09, 159 530000 ± 197990, 530000 
15-19 319 ± 390, 98  
20-29 89 ± 153, 36 138221 ± 228521, 10000 
30-39 97 ± 217, 36 120652 ± 186180, 10000 
40-49 59 ± 77, 33 286101.8 ± 356667.7, 67500 
50-59 107 ± 112, 63 220100 ± 426624, 10000 
60+ 70 ± 72, 32 49000 ± 55154, 49000 
Gender**   
  Male 111 ± 200, 40 189316 ± 276365, 10000 
  Female 146 ± 302, 42 158536 ± 224884, 13000 
Year***   
  2003  93 ± 130, 39 ------ 
  2004  111 ± 221, 39 ------ 
  2005  150 ± 269, 45 309038 ± 268503, 230000 
  2006  140 ± 302, 40 8933 ± 3051, 10000 
* Kruskal-Wallis test: Chi squared = 62.171, p = 0.0001 for CD4; Chi squared = 8.258, 
p = 0.409 for viral load. 
** Wilcoxon rank sum test: p = 0.271 for CD4; p = 0.841 for viral load. 
*** Kruskal-Wallis test: Chi squared = 1.136, p = 0.769 for CD4; Wilcoxon rank sum test, 
 p = 0.0001 for viral load. 
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3.4 Association of HIV serostatus with mortality and clinical-microbiologic 
features  
3.4.1 Mortality  
The overall mortality was 32.22% but significantly higher (p<0.001) in HIV positive 
patients (35.79%) than in HIV negative patients (15.55%).  After excluding patients who 
died within three days post admission, the mortality proportion was 29.17% in HIV 
positive and 12.23% in HIV negative patients but the difference remained statistically 
significant (p<0.001). Mean/median hospital stay before death was not statistically 
different between HIV positive and negative patients. Most HIV positive patients who died 
were males (51.79%) aged between 30 and 49 years (51.91%), admitted in academic 
hospitals in 2005 (28.64%) while most HIV negative patients who died were males 
(54.05%) aged above 50 years (32.43%), admitted in academic hospitals in 2005 (13.51%). 
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Table 3.5 Distribution of mortality in HIV positive and negative patients by age groups, 
gender, hospital status and year of surveillance 
HIV status  
Positive % (n) Negative % (n) 
P-value 
Final outcome 
i
 (n = 1 350)   0.0001 
  Died 35.79 (398) 15.55 (37)  
  Survived 64.21 (714) 84.45 (201)  
Final outcome 
ii 
(n = 1 237)   0.0001 
  Died 29.17 (294) 12.23 (28)  
  Survived 70.83 (714) 87.77 (201)  
Mortality within three days of admission   61.90 (104) 40.91 (9) 0.059  
Hospital stay before death (days) (mean ± 
SD, median)
 
9.38 ± 15.66, 5 10.13 ± 11.38, 5 0.642* 
Age groups
§
    
  <1 14.50 (57) 27.03 (10)  
  1-9 6.62 (26) 8.11 (3)  
  10-29 19.34 (76) 10.81 (4)  
  30-49 51.91 (204) 21.62 (8)  
  50+ 7.63 (30) 32.43 (12)  
Gender
§
     
  Male 51.79 (202) 54.05 (20)  
  Female 48.21 (188) 45.95 (17)  
Hospital     
  Academic 90.45 (360) 83.78 (31)  
  Non academic 9.55 (38) 16.22 (6)  
Year    
  2003 22.36 (89) 21.62 (8)  
  2004 26.13 (104) 35.14 (13)  
  2005 28.64 (114) 13.51 (5)  
  2006 22.86 (91) 29.73 (11)  
* P value based on Wilcoxon rank sum test, otherwise the rest are based on Pearson chi 
squared test. 
i 
Total number of those who died and those who survived. 
ii
 Excludes number of patients who died within three days of admission.   
§
 Mortality by age groups and gender. Total HIV positive number do not add up to 398 due 
to missing observations. 
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3.4.2 Population attributable fraction of mortality due to HIV 
 
It is estimated that 55% of deaths in patients with invasive NTS infection admitted between 
2003 and 2006 were attributed to HIV infection using the formula below: 
PAF = p (OR- 1)/p (OR-1) + 1 
        = 0.82(2.50-1)/ 0.82(2.50-1) + 1 
        = 0.552 
        = 55.20% 
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3.4.3 Clinical-microbiologic features 
More HIV positive patients (32.86%) than HIV negative patients (19.54%) were not alert 
on mental status examination (Table 3.5). The differences in lower respiratory tract 
infections were statistically significant (p<0.05) and more common in HIV positive 
patients (37.73%) than in HIV negative patients (22.76%). Gastroenteritis, bacteraemia 
without focus and other diagnoses were less common in HIV positive patients than HIV 
negative patients each at 21.81%, 30.78%, and 1.85% compared to 30.08%, 37.80%, and 
4.47% respectively. These differences were statistically significant (p<0.05). 
HIV positive patients had statistically significant (p<0.001) less mean length of hospital 
stay of 11.18 days compared to 16.54 days of HIV negative patients. This difference was 
also observed among patients who survived, whose length of hospital stay was 12.18 days 
in HIV positive patients and 17.56 days in HIV negative patients. HIV positive patients 
had more recurrence of NTS infections (6.02%) than HIV negative patients (1.98%) 
(p<0.05). 
There were no statistical differences (p>0.05) in temperature, BP, cardiac arrest and 
meningitis between HIV positive and negative patients. 
Salmonella Typhimurium and other serotypes were found to be significantly different by 
HIV serostatus (p<0.001). More HIV positive patients (67.04%) than HIV negative 
patients (37.10%) had Salmonella Typhimurium and less HIV positive patients (14.70%) 
had other serotypes than HIV negative patients (44.35%). 
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Table 3.6 Distribution of clinical-microbiologic features in HIV positive and negative 
patients 
HIV status  
Positive % (n) Negative % (n) 
  P-value 
Temperature 
i
 (n = 1 042) 7.61 (64) 8.46 (17) 0.203 
BP 
ii 
(n = 882) 24.66(182) 20.14 (29) 0.245 
Cardiac arrest * (n = 961) 0.91 (7) 0.52 (1) 1.000 
Mental status: (n = 953)   0.001 
  Alert 67.14 (523) 80.46 (140)  
  Not alert 
iii
 32.86 (256) 19.54 (34)  
Diagnosis: (n = 1 383)    
  Meningitis 7.83 (89) 4.88 (12) 0.107 
  LRTI 37.73 (429) 22.76 (56) 0.0001 
  Gastroenteritis 
iv
 21.81 (248) 30.08 (74) 0.005 
  Bacteraemia without focus 30.78 (350) 37.80 (93) 0.032 
  Other
 v
 1.85 (21) 4.47 (11) 0.013 
Length of hospital stay (days) 
vi
 
(mean ± SD, median) 
11.18 ± 13.74, 8 16.54 ± 22.98, 11 0.0001 
Length of hospital stay among 
survivors (days) 
vi 
(mean ± SD, 
median) 
12.18 ± 12.50, 9 17.56 ± 24.20, 12 0.003 
NTS recurrence
 vii
 (n = 1 483) 6.02 (74) 1.98 (5) 0.009 
Specimen site * (n = 1 398)   0.156 
  CSF 3.48 (40) 1.21 (3)  
  Blood 94.17 (1 083) 96.77 (240)  
  Other 2.35 (27) 2.02 (5)  
Serotypes
 vii
    
   Typhimurium 67.04 (771) 37.10 (92) 0.0001 
   Enteritidis 8.17 (94) 6.05 (15) 0.258 
   Isangi 5.39 (62) 7.66 (19) 0.165 
   Dublin 3.83 (44) 3.23 (8) 0.651 
   Schwarzengrund * 0.87 (10) 1.61 (4) 0.290 
   Other§ 14.70 (169) 44.35 (110) 0.0001 
i
 Temperature was pre-coded in the dataset into three categories 0=36.1-38.9 °C, 1=36 °C 
or 39 °C and 2= (=>40 °C or <=35 °C). The frequencies displayed here are for the last 
category (code 2). 
ii
 BP was pre-coded in the dataset into two categories of diastolic pressure 0 = >91 mmhg 
and 2=<90mmhg. The frequencies displayed here are for the last category (code 2). 
iii 
Includes disorientated, stuporose and comatose. 
iv
 Includes diarrhoea and dysentery. 
v
 Other diagnoses include arthritis, burn, abscess, upper respiratory tract infections, pelvic 
inflammation disease and urinary tract infection. 
vi 
P – value calculated by Wilcoxon rank-sum test due to skewed distribution of length of 
hospital stay.  
vii P-value calculated by Pearson chi-squared test unless otherwise stated. 
* P-value calculated by Fisher’s exact test. 
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§Include serotypes  Aberdeen, Anatum, Bovismorbificans, Bradford, Braenderup, 
Bredeney, Eppendorf, Essen, Hadar, Heidelberg, Hvittingfoss, Infantis, Irumu, Kibusi, 
Kisangani,   Larochelle, Minnesota, Molade, Muenchen, Newport, Othmarschen, Panama, 
Powell, Ramsey, Roodepoort, Saintpaul, non-typeable species, Stanleyville, Virchow, 
Virginia. 
 
3.4.4 Univariate and multivariate logistic regression models for mortality 
In univariate analysis, factors associated with mortality were HIV positive serostatus (OR 
= 3.03, 95% CI 2.089 - 4.390); age (OR = 1.02, 95% CI 1.009 - 1.023); Limpopo +  
Mpumalanga + Kwa Zulu Natal provinces (OR = 2.57, 95% CI 1.506 - 4.389); Free State + 
Gauteng provinces (OR = 2.48, 95% CI 1.626 - 3.769); antimicrobial usage (OR =  0.73, 
95% CI  0.563 - 0.950) and meningitis (OR = 2.34, 95% CI 1.544 - 3.560). 
After adjusting for age, province, antimicrobial usage and meningitis in multivariate 
analysis, HIV positive patients were more likely to die (OR = 2.50, 95% CI 1.690 - 3.698)   
than HIV negative patients (Table 3.7). 
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Table 3.7 Single and multiple modeled risk factors associated with mortality 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model * 
OR (95% CI) p-value 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
3.03 (2.089 - 4.390) 0.000 2.50 (1.690 - 3.698) 0.000 
Age 1.02 (1.009 - 1.023) 0.000 1.01 (1.003 - 1.017) 0.004 
Gender  
 Female  1.00 (reference) 
 Male 1.130 (0.897 - 1.423) 0.300 
Province 
i
  
 
 EC+WC 1.00 (reference) 1.00 (reference) 
 LP+MP+KZ 2.57 (1.506 - 4.389) 0.001 2.09 (1.196 - 3.639) 0.010 
 FS+GA 2.48 (1.626 - 3.769) 0.000 1.55 (0.983 - 2.438) 0.059 
Hospital 
 
 
 Non-academic 1.00 (reference) 
 Academic 1.28 (0.884 - 1.845) 0.192 
Antimicrobial usage  
 
 No 1.00 (reference) 1.00 (reference) 
 Yes 0.73 (0.563 - 0.950) 0.019 0.778 (0.594 - 1.020) 0.070 
Immuno
 ii
  
 Absent 1.00 (reference) 
 Present 1.25 (0.985 - 1.585) 0.067 
Diagnosis  
 
 Meningitis 2.34 (1.544 - 3.560) 0.000 2.29 (1.493 - 3.522) 0.000 
 LRTI 1.10 (0.865 - 1.392) 0.445 
 Gastroenteritis 0.86 (0.651 - 1.125) 0.263 
 Bacteraemia without focus 0.82 (0.635 - 1.048) 0.112 
 Other 0.52 (0.211 - 1.280) 0.154 
 
Year  
 2003 1.00 (reference) 
 2004 0.94 (0.674 - 1.308) 0.711 
 2005 0.84 (0.602 - 1.158) 0.279 
 2006 0.84 (0.601 - 1.185) 0.327 
 
i
Provinces were collapsed into three groups according to geographical proximity to allow 
for efficient control in logistic regression. EC, Eastern Cape; FS, Free State; GA, Gauteng; 
KZ, Kwa Zulu Natal; LP, Limpopo; MP, Mpumalanga; WC, Western Cape. 
ii
Immuno, immunosuppressive conditions.  
* Likelihood ratio statistic chi-squared = 77.09, (df = 6, p = 0.0000); Pseudo R
2
 = 0.0459; 
Hosmer-Lemeshow goodness of fit chi-squared = 10.06, (df = 8, p  = 0.2608). 
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3.4.5 Univariate and multivariate logistic regression models for not being alert 
In univariate analysis, HIV positive patients were more likely to be not alert than HIV 
negative patients (OR = 2.02, 95% CI 1.346 - 3.017). After adjusting for province and 
diagnosis in multivariate model, the association was not significant (OR = 1.47, 95% CI 
0.963 - 2.259). Not being alert was rather associated with meningitis (OR = 2.38, 95% CI 
1.434 - 3.957) and living in Free state and Gauteng province (OR = 3.11, 95% CI 1.736 - 
5.580) (Table 3.8).   
 
Table 3.8 Single and multiple modeled risk factors associated with not being alert 
 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model*  
 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
2.02 (1.346 - 3.017) 0.001 1.47 (0.963 - 2.259) 0.074 
Age 1.01 (1.006 – 1.021) 0.001  
Province   
 EC+WC 1.00 (reference) 1.00 (reference) 
 LP+MP+KZ 0.904 (0.414 – 1.976) 0.801  
 FS+GA 3.465 (1.968 – 6.100) 0.000 3.11 (1.736 - 5.580) 0.000 
Hospital 
 
 
 Non-academic 1.00 (reference) 
 Academic 3.19 (1.846 – 5.499) 0.000 
Antimicrobial usage  
 No 1.00 (reference) 
 Yes 0.475 (0.280 – 0.804) 0.006 
Diagnosis  
 
 Meningitis 2.31 (1.416 – 3.779) 0.001 2.38 (1.434 - 3.957) 0.001 
 LRTI 0.93 (0.697 – 1.245) 0.632 
 Gastroenteritis 0.86 (0.602 – 1.236) 0.421 
 Bacteraemia without focus 0.99 (0.741 – 1.316) 0.931 
 Other 0.264 (0.061 – 1.150) 0.076 
 
* Likelihood ratio statistic chi-squared = 59.89, (df = 4, p = 0.0000); Pseudo R
2
 = 0.0511; 
Hosmer-Lemeshow goodness of fit chi-squared = 0.12, (df = 3, p  = 0.9897). 
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3.4.6 Univariate and multivariate logistic regression models for LRTI 
 
In univariate model, HIV positive patients were more likely than HIV negative patients to 
have LRTI (OR = 2.06, 95% CI 1.491 - 2.835). After adjusting for province and 
immunosuppressive conditions in multivariate model, the association was almost similar 
(OR = 1.89, 95% CI 1.342- 2.647). Immunosuppressive conditions were an effect modifier 
in association between HIV serostatus and LRTI. The association between HIV positive 
serostatus and LRTI was observed in presence of immunosuppressive conditions (OR 
=2.43, 95% CI 1.518 - 3.887) but not in its absence (OR = 1.48, 95% CI 0.893 - 2.467) 
(Table 3.9). 
 
Table 3.9 Single and multiple modeled risk factors associated with LRTI 
 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model*  
 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
2.06 (1.491 - 2.835) 0.000 1.89 (1.342- 2.647) 0.000 
  Immuno absent  1.48 (0.893 - 2.467) 0.128 
  Immuno present  2.43 (1.518 - 3.887) 0.000 
Age 1.00 (0.993 – 1.006) 0.907 0.99 (0.988 – 1.001) 0.071 
Province   
 EC+WC 1.00 (reference) 1.00 (reference) 
 LP+MP+KZ 1.24 (0.756 – 2.045) 0.390  
 FS+GA 1.71 (1.187 – 2.457) 0.004 1.54 (1.037 - 2.282) 0.032 
Antimicrobial usage  
 No 1.00 (reference) 
 Yes 1.18 (0.910 – 1.538) 0.209 
Immuno  
 
 Absent 1.00 (reference) 1.00 (reference) 
 Present 1.50 (1.188 – 1.888) 0.001 1.40 (1.103 - 1.767) 0.005 
* Likelihood ratio statistic chi-squared = 36.09, (df = 5, p = 0.0000); Pseudo R
2
 = 0.0201; 
Hosmer-Lemeshow goodness of fit chi-squared = 7.82, (df = 8, p = 0.4515). 
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3.4.7 Univariate and multivariate logistic regression models for NTS recurrence 
 
In univariate model, HIV positive patients were more likely than HIV negative patients to 
have recurrent NTS infections (OR = 3.18, 95% CI 1.270 - 7.935). After adjusting for year 
of surveillance in multivariate model, the magnitude of association increased (OR = 3.90, 
95%CI 1.409 - 10.769) (Table 3.10). 
 
Table 3.10 Single and multiple modeled risk factors associated with NTS recurrence 
 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model* 
OR (95% CI) p-value 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
3.18  (1.270 - 7.935) 0.013 3.90 (1.409 - 10.769) 0.009 
Diagnosis  
 Meningitis 1.39 (0.620 – 3.099) 0.426 
 LRTI 0.82 (0.504 – 1.348) 0.441 
 Gastroenteritis 0.80 (0.315 – 2.007) 0.627 
 Bacteraemia without focus 1.00 (0.617 – 1.635) 0.986 
 Other 0.63 (0.085 – 4.691) 0.652 
Year  
 
 2003 1.00 (reference) 1.00 (reference) 
 2004 1.70 (0.891 – 3.247) 0.108 1.76 (1.096 – 2.833) 0.019 
 2005 1.11 (0.557 – 2.203) 0.770 
 2006 0.65 (0.289 – 1.445) 0.288 
 
* Likelihood ratio statistic chi-squared = 15.39, (df = 2, p = 0.0005); Pseudo R
2
 = 0.0255; 
Hosmer-Lemeshow goodness of fit chi-squared = 0.20, (df = 1, p  = 0.6561). 
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3.4.8 Univariate and multivariate logistic regression models for hospital stay of less 
than 16 days 
In univariate model, HIV positive patients were more likely than HIV negative patients to 
stay less that 16 days in the hospital (OR = 1.98, 95% CI 1.361 - 2.876). After adjusting for 
age, antimicrobial usage and immunosuppressive conditions in multivariate model, the 
association slightly decreased (OR = 1.61, 95% CI 1.075 – 2.403). Patients who used 
antimicrobials (OR = 0.43, 95% CI 0.223 – 0.847) and had immunosuppressive conditions 
(OR = 0.65, 95% CI 0.431 -0.984) were more likely to stay longer than 16 days in the 
hospital (Table 3.11). 
 
Table 3.11 Single and multiple modeled risk factors associated with hospital stay of less 
than 16 days
 *
 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model
**
 
OR (95% CI) p-value 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
1.98 (1.361 - 2.876) 0.000 1.61 (1.075 - 2.403) 0.021 
Age 1.03 (1.018 – 1.036) 0.000 1.02 (1.014 – 1.033) 0.000 
Province  
 EC+WC 1.00 (reference) 
 LP+MP+KZ 1.31 (0.720 – 2.365) 0.380 
 FS+GA 2.068 (1.365 – 3.133) 0.001 
Hospital 
 
 
 Non-academic 1.00 (reference) 
 Academic 1.44 (0.927 – 2.230) 0.105 
Antimicrobial usage  
 
 No 1.00 (reference) 1.00 (reference) 
 Yes 0.620 (0.429 – 0.898) 0.011 0.43 (0.223 – 0.847) 0.014 
Immuno   
 Absent 1.00 (reference) 1.00 (reference) 
 Present 0.73 (0.509 – 1.048) 0.088 0.65 (0.431 -0.984) 0.041 
*
Length of hospital stay was categorized into below and above 16 days in accordance with 
published literature (Helms et al., 2006).  
**
Likelihood ratio statistic chi-squared = 53.47, (df = 6, p = 0.0000); Pseudo R
2
 = 0.0556; 
Hosmer-Lemeshow goodness of fit chi-squared = 2.73, (df = 8, p  = 0.9500). 
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3.4.9 Univariate and multivariate logistic regression models for Salmonella  
Typhimurium 
In univariate model, HIV positive patients were more likely than HIV negative patients to 
be infected with Salmonella Typhimurium (OR = 3.45, 95% CI 2.593 – 4.589). After 
adjusting for age, type of hospital, diagnosis and year of surveillance in multivariate 
model, the association remained the same (OR = 2.59, 95% CI 1.910 - 3.507). LRTI was 
associated with Salmonella Typhimurium (OR = 1.38, 95% CI 1.081 – 1.767) (Table 3.12). 
 
Table 3.12 Single and multiple modeled risk factors associated with Salmonella  
Typhimurium 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model* 
OR (95% CI) p-value 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
3.45 (2.593 -   4.589) 0.000 2.59 (1.910 - 3.507) 0.000 
Age 1.03 (1.020 – 1.032) 0.000 1.02 (1.013 – 1.026) 0.000 
Hospital 
 
  
 Non-academic 1.00 (reference) 1.00 (reference) 
 Academic 2.72 (1.945 – 3.801) 0.000 1.89 (1.314 – 2.717) 0.001 
Diagnosis   
 Meningitis 1.08 (0.708 – 1.641) 0.726  
 LRTI 1.50 (1.187 – 1.887) 0.001 1.38 (1.081 – 1.767) 0.010 
 Gastroenteritis 0.60 (0.465 – 0.769) 0.000  
 Bacteraemia without focus 1.07 (0.845 – 1.345) 0.592  
 Other 0.61 (0.304 – 1.236) 0.171  
Year   
 2003 1.00 (reference) 1.00 (reference) 
 2004 1.02 (0.743 – 1.395) 0.912 
 2005 0.99 (0.725 – 1.349) 0.942 
 
 2006 1.46 (1.048 – 2.024) 0.025 1.68 (1.182 – 2.389) 0.004 
* Likelihood ratio statistic chi-squared = 147.82, (df = 7, p = 0.0000); Pseudo R
2
 = 0.0802; 
Hosmer-Lemeshow goodness of fit chi-squared = 13.14, (df = 8, p = 0.1071).  
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3.4.10 Univariate and multivariate logistic regression models for Gastroenteritis 
In the respective univariate and multivariate models, HIV positive patients were less likely 
than HIV negative patients to suffer from gastroenteritis (OR = 0.65, 95% CI 0.477 - 
0.881) (OR = 0.66, 95% CI 0.468 - 0.920) (Table 3.13). 
 
Table 3.13 Single and multiple modeled risk factors associated with gastroenteritis 
 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model* 
OR (95% CI) p-value 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
0.65 (0.477 -  0.881) 0.006 0.66 (0.468 - 0.920) 0.014 
Age 0.988 (0.981 – 0.995) 0.000 0.99 (0.982 - 0.996) 0.003 
Province  
 EC+WC 1.00 (reference) 
 LP+MP+KZ 0.89 (0.544 – 1.455) 0.641 
 FS+GA 0.63 (0.441 – 0.900) 0.011 
Antimicrobial usage  
 No 1.00 (reference) 
 Yes 0.50 (0.383 – 0.662) 0.000 
Immuno  
 Absent 1.00 (reference) 
 Present 0.60 (0.467 – 0.773) 0.000 
Year  
 
 2003 1.00 (reference) 1.00 (reference) 
 2004 0.71 (0.511 - 0.974) 0.034 0.70 (0.504 - 0.972) 0.033 
 2005 0.30 (0.211 - 0.431) 0.000 0.28 (0.197 - 0.409) 0.000 
 2006 0.12 (0.074 - 0.191) 0.000 0.119 (0.073 - 0.193) 0.000 
* Likelihood ratio statistic chi-squared = 136.13, (df = 5, p = 0.0000); Pseudo R
2
 = 0.0922; 
Hosmer-Lemeshow goodness of fit chi-squared = 11.95, (df = 8, p = 0.1534). 
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3.4.11 Univariate and multivariate logistic regression models for bacteraemia 
without focus 
In the respective univariate and multivariate models, HIV positive patients were less likely 
than HIV negative patients to suffer from bacteraemia without focus (OR = 0.73, 95% CI 
0.549 - 0.975) (OR = 0.66, 95% CI 0.505 - 0.943) (Table 3.14). 
 
Table 3.14 Single and multiple modeled risk factors associated with bacteraemia without                    
focus 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model* 
OR (95% CI) p-value 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
0.73 (0.549 - 0.975) 0.033 0.66 (0.505 - 0.943) 0.011 
Age 1.01 (1.001 – 1.014) 0.017 1.01 (1.003 – 1.016) 0.005 
Gender  
 Female  1.00 (reference) 
 Male 1.27 (1.009 – 1.593) 0.042 
Antimicrobial usage  
 
 No 1.00 (reference) 1.00 (reference) 
 Yes 2.03 (1.512 – 2.712) 0.000 0.67 (0.430 – 1.040) 0.074 
Year   
 2003 1.00 (reference) 1.00 (reference) 
 2004 2.82 (1.837 – 4.327) 0.000 3.84 (2.188 – 6.743) 0.000 
 2005 4.23 (2.789 – 6.420) 0.000 5.93 (3.371 – 10.426) 0.000 
 2006 6.99 (4.594 – 10.649) 0.000 9.12 (5.201 – 15.986) 0.000 
* Likelihood ratio statistic chi-squared = 116.73, (df = 6, p = 0.0000); Pseudo R
2
 = 0.0678; 
Hosmer-Lemeshow goodness of fit chi-squared = 3.73, (df = 8, p = 0.8806). 
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3.4.12 Univariate and multivariate logistic regression models for other diagnosis 
In univariate model, HIV positive patients were less likely than HIV negative patients to 
have other diagnosis (OR = 0.40, 95% CI 0.191 - 0.845). In multivariate model the 
association was not significant (OR = 0.64, 95% CI 0.276 - 1.46) (Table 3.15). 
 
Table 3.15 Single and multiple modeled risk factors associated with other diagnosis 
 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model* 
OR (95% CI) p-value 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
0.40 (0.191 - 0.845) 0.016 0.64 (0.276 - 1.46) 0.286 
Age 1.01 (0.990 – 1.029) 0.334 1.02 (1.005 – 1.044) 0.014 
Province   
 EC+WC 1.00 (reference) 1.00 (reference) 
 LP+MP+KZ 0.54 (0.184 – 1.597) 0.266  
 FS+GA 0.22 (0.101 – 0.484) 0.000 0.16 (0.062 – 0.409) 0.000 
Hospital 
 
 
 Non-academic 1.00 (reference) 
 Academic 0.32 (0.147 – 0.709) 0.005 
Year  
 
 2003 1.00 (reference) 1.00 (reference) 
 2004 1.75 (0.711 – 4.315) 0.224 
 2005 0.70 (0.244 – 2.028) 0.515 
 
 2006 0.23 (0.048 – 1.118) 0.069 0.22 (0.045 – 1.091) 0.064 
* Likelihood ratio statistic chi-squared = 32.73, (df = 7, p = 0.0000); Pseudo R
2
 = 0.1075; 
Hosmer-Lemeshow goodness of fit chi-squared = 5.88, (df = 8, p = 0.6605). 
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3.4.13 Univariate and multivariate logistic regression models for other Salmonella  
serotypes 
In univariate and multivariate models, HIV positive patients were less likely than HIV 
negative patients to be infected with other Salmonella serotypes  
(OR = 0.22, 95%CI 0.160 – 0.291) and (OR = 0.99, 95% CI 0.982 – 0.997) respectively. 
Gastroenteritis was associated with other Salmonella serotypes  
(OR = 1.42, 95% CI 1.034 – 1.948) (Table 3.16). 
 
Table 3.16 Single and multiple modeled risk factors associated with other Salmonella 
serotypes 
Factor Univariate Model 
OR (95% CI) p-value 
Multivariate model* 
OR (95% CI) p-value 
HIV status   
 Negative 1.00 (reference) 1.00 (reference) 
 Positive 
 
0.22 (0.160 - 0.291) 0.000 0.28 (0.206 - 0.389) 0.000 
Age 0.98 (0.971 – 0.986) 0.000 0.99 (0.982 – 0.997) 0.009 
Hospital 
 
  
 Non-academic 1.00 (reference) 1.00 (reference) 
 Academic 0.26 (0.184 – 0.366) 0.000 0.35 (0.244 – 0.513) 0.000 
Immuno  
 Absent 1.00 (reference) 
 Present 0.704 (0.540 – 0.918) 0.01 
Diagnosis  
 Meningitis 1.20 (0.738 – 1.947) 0.463 
 LRTI 0.54 (0.402 – 0.732) 0.000 
 
 Gastroenteritis 1.53 (1.136 – 2.047) 0.005 1.42 (1.034 – 1.948) 0.030  
 Bacteraemia without focus 1.14 (0.866 – 1.511) 0.343 
 Other 1.85 (0.868 – 3.961) 0.111 
 
* Likelihood ratio statistic chi-squared = 141.15, (df = 4, p = 0.0000); Pseudo R
2
 = 0.1020; 
Hosmer-Lemeshow goodness of fit chi-squared = 8.75, (df = 8, p = 0.3635). 
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CHAPTER 4 
4.0 DISCUSSION 
Information on the effect of HIV on opportunistic diseases is important for managing 
patients with dual HIV and NTS infection and recommending for HIV care and treatment 
policy. This study was carried out to determine the impact of HIV on clinical-
microbiologic features and mortality among patients with invasive nontyphoidal 
Salmonella infection in South Africa. 
The study found that among 1 398 patients with invasive nontyphoidal Salmonella, the 
overall mortality was 32% and HIV infection was independently associated with higher 
mortality and 55% of these deaths were attributable to HIV infection. It was also found that 
LRTI, recurrence of invasive NTS, shorter duration of hospital stay of less than 16 days 
and Salmonella serotype Typhimurium infection were associated with HIV infection.  
Furthermore, HIV positive patients were less likely than HIV negative patients to suffer 
from gastroenteritis, bacteraemia without focus and other Salmonella serotypes. 
The HIV prevalence in this study population was higher than that of the general population 
(Dorrington, et al., 2006). The frequency pattern of HIV positive status by age groups 
coincided with that of invasive NTS infection, with age groups 20-29 and 30-39 having the 
highest proportions of HIV positive status. Despite the rise in the ARV usage trend by year 
of surveillance, ARV usage was generally low compared to the recent national figure 
(WHO, 2006) and gender differences were observed with more males using ARVs than 
females. Lastly, a higher proportion of HIV positive patients used antimicrobials than HIV 
negative patients. 
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Impact of HIV on mortality 
 
The association of HIV with mortality in patients with NTS has also been demonstrated by 
a previous study conducted among paediatric patients in Africa (Graham, et al., 2000a). To 
the contrary, one study conducted by Fisk, et al., (2005) among adult patients in the United 
States of America showed no association of HIV and mortality in patients with NTS. 
However the study was limited by a small sample size that led to failure in eliciting the 
HIV-mortality association. 
The current study combined both children and adults and quantified the magnitude of HIV-
mortality association. Moreover the impact of HIV on mortality was shown by the use of 
population attributable faction, which has not been considered before. The study found that 
55% of deaths would have been avoided in patients with invasive NTS, if HIV 
transmission could have been prevented in this study population.  
Generally invasive NTS is independently associated with high mortality (Graham, et al., 
2000b; Gordon, et al., 2002). Nevertheless patients with dual HIV-invasive NTS infection 
have excess mortality due to immunosuppression caused by HIV infection resulting into 
increased disease severity and probably resistance to antimicrobials by invasive NTS and 
eventually death. Another study is currently underway, looking at the relationship between 
HIV serostatus and antimicrobial resistance patterns in patients with NTS.  
 
Association of HIV with clinical features 
Most previous studies have reported clinical presentation of invasive NTS in general 
(Gordon, et al., 2000; Graham, et al., 2000a) with the exception of the study by Gordon, et 
al., (2002) which reported clinical presentation of NTS in a 99% HIV positive study 
population. The current study compared clinical features of invasive NTS between HIV 
positive and negative patients despite the limited amount of collected information. This 
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study compared and quantified the association between HIV infection with LRTI, duration 
of hospital stay and invasive NTS recurrence.  
The association of HIV and LRTI in patients with invasive NTS could be due to the NTS 
predilection to damaged tissues (Casado, et al., 1997; Charles, et al., 1998; Lin, et al., 
2006). This was shown in the study by the effect modification of immunosuppressive 
conditions, whose presence gave odds ratio of two in the association of HIV and LRTI 
while its absence gave odds ratio of 1.5 that was statistically not significant. This implies 
that respiratory conditions like TB and PCP (collapsed into immunosuppressive 
conditions) in HIV positive patients played a major role in predisposing the lungs to NTS 
infection. It is most unlikely that the LRTI was directly due to PCP or TB rather than NTS 
itself because the two OIs were controlled for in the multivariate analysis. Since the 
diagnosis of NTS was confirmed through blood in this study population, the LRTI was due 
to lung invasion by NTS through the haematogenous route. Others have also reported lung 
involvement by NTS (Casado, et al., 1997; Mankhambo, et al., 2006; Ridha, et al., 1996; 
Zaidi, et al., 1999). This study however was limited in clinical and laboratory information 
in ascertaining whether it was pneumonia or lung abscess and confirmation by chest x-ray, 
isolation of NTS from sputum and pleural fluid, ruling out co-infections by other 
organisms like Streptococcus pneumoniae respectively. 
The shorter duration of hospital stay of less than 16 days among HIV positive patients was 
an unexpected finding and in contrast to other studies that found no differences in hospital 
duration by HIV status in invasive NTS patients (Fisk, et al.,2005) and general patients 
(Arthur, et al.,2000; Bhagwanjee, et al., 1997; Palmer, et al., 2000). It was expected that 
HIV patients would stay longer in hospitals due to the associated severity of clinical 
conditions. It was thought that the higher mortality in HIV positive patients was 
responsible for the shorter duration of hospital stay but this was unlikely because in the 
sub-analysis among all survivors, HIV positive patients continued to have a shorter 
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duration of hospital stay. Probably HIV positive patients are discharged early or transferred 
to HIV care units after the diagnosis of HIV is confirmed. It could also be due to a short 
term effect of quicker clinical improvement from either more effective antimicrobials 
prescribed or the synergistic action of ARVs and antimicrobials. Zidovudine has been 
shown to have activity against Salmonella (Casado, et al., 1999). A further research on 
doctors’ practices towards discharge of patients, antimicrobial prescribing patterns in 
relation to HIV serostatus and combined ARVs-antimicrobials effects is warranted.   
This study replicates the findings by Gordon, et al., (2002) that invasive NTS recurrence is 
a common feature of HIV by a comparative analysis of HIV positive and negative patients, 
which was not considered in the previous study. However Gordon, et al., (2002) described 
the pattern of recurrence and showed it was mainly due to recrudescence rather than re-
infection. The differentiation of these two features associated with recurrence was not 
considered in the current study due to limitation in amount of collected information. 
The finding that HIV positive serostatus is less likely to be associated with gastroenteritis 
and bacteraemia without focus adds to the fact that HIV infection is associated with more 
severe and not less severe clinical conditions. There was a limitation in objective 
assessment of severity of different clinical conditions. Ideally, this should have been 
achieved by a comparative analysis of severity scores such as GCS by HIV serostatus but 
information on GCS were extensively missing and therefore were excluded from analysis. 
Kariuki, et al., (2006) in Kenya have reported gastroenteritis and bacteraemia without 
focus in paediatric NTS patients with unknown HIV status. 
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Association of HIV with microbiologic features 
Many previous studies have not considered the association of HIV infection and 
Salmonella serotypes. This study found that HIV positive serostatus is associated with 
Salmonella serotype Typhimurium which is contrary to the previous studies that showed a 
relationship between HIV and Salmonella serotype Enteritidis (Chierakul, et al., 2004; 
Levine, et al., 1991). The design of these studies was ecological and therefore the evidence 
for the association was weak. Studies conducted in African populations with high HIV 
prevalence have shown that Salmonella Typhimurium is the predominant invasive serotype 
(Gordon, et al., 2002; Graham, et al., 2000a; Kruger, et al., 2004). This implies that 
Salmonella Typhimurium has a propensity to infect HIV patients, which has been 
confirmed by the current study through controlling for other serotypes.  
 
HIV prevalence 
High prevalence of HIV among patients with invasive NTS has also been reported by 
Gordon, et al., (2002). This is because HIV is a risk factor for NTS infection (Hohmann, 
2001; Levine, et al., 1991; Pithie, et al., 1993).  It is most unlikely that the prevalence 
estimate in this study is far from the true value because most patients with unknown HIV 
status could be HIV positive as well.  
For the first time, this study has described the pattern of HIV positive serostatus among 
patients with invasive NTS according to age groups which showed that the age groups  
20-29 and 30-39 are the most affected, reflecting HIV prevalence in the general population 
(Dorrington, et al., 2006). The correlation of frequency of HIV positive pattern and that of 
invasive NTS according to age groups suggests that the latter can be used as a proxy in 
estimating HIV prevalence, but this needs further modeling and control of all known OIs.   
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Antiretroviral and antimicrobial usage 
The rise in ARV usage trend by years reflects an improvement in their roll out in the 
country although it might reflect improvement in data collection as well. The lower ARV 
usage than the national estimate (WHO, 2006) could be due to missing data. Otherwise, it 
could be reflecting the fact that most of these HIV patients did not take ARVs initially and 
eventually got infected with invasive NTS.  
The finding of more men accessing ARVs than women is different from the previous study 
by Conradie, et al., (2005) conducted among HIV positive patients in a tertiary hospital in 
South Africa. The current study showed that the dynamics of HIV-NTS patients may be 
different from the general HIV patients’ population. In general, studies conducted in 
various settings, have found either no gender differences or differences in ARV usage 
(WHO, 2006). The reasons for observed gender differences could be social-cultural which 
need to be researched further. 
More antimicrobial usage in HIV positive patients is due to the higher burden and severity 
of opportunistic infections, which is not the case in HIV negative patients. Palmer, et al., 
(2000), has also reported the use of more antimicrobials in HIV positive than HIV negative 
patients. 
 
Limitations 
The major limitation of this study was missing information, which is common in 
surveillance data. The absence of information has affected the study in a number of ways. 
Firstly, patients with unknown HIV status differed in mean age by being three years 
younger than patients with known HIV status and other social demographic characteristics 
like provinces, hospitals and year of surveillance. Therefore, these findings cannot be 
generalized to the former group. Secondly, differential missing by HIV status contributed 
to insignificant association for variables like temperature and cardiac arrest. Thirdly, 
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absence of more than 50% led to the exclusion from analysis of variables like number of 
previous admissions and GCS. Other variables excluded in the analysis were the diagnosis 
of mixed serotypes and infections due to small sample size resulting from a non routine 
procedure for their laboratory diagnosis. 
Although the analyzed variables had also missing observations, these were neither greater 
than 50% nor were there differential by HIV serostatus except for CD4 count.  In principle, 
methods of dealing with missing data were put in place (D’agostino and Rubin, 2000; 
Faris, et al., 2002; Lubeck, et al., 1999; Norris, et al.,2000; Rothman and Greenland, 1998; 
Schoenbach and Rosamond, 2000) but they are laborious and complex (Rothman and 
Greenland, 1998; Schoenbach and Rosamond, 2000). Therefore, it was decided to exclude 
the missing observations in the analysis. Although this is simple and commended by some 
authorities (Rothman and Greenland, 1998) it might have introduced selection bias 
(Schoenbach and Rosamond, 2000) and again the results cannot be generalized to patients 
with unknown HIV status. It is most unlikely that information bias affected this study 
because the collection of other clinical information preceded that of HIV status and 
serotyping was done without prior knowledge of HIV status. 
 
Other limitations include the categorization of temperature and BP in the dataset. 
Temperature was pre-coded into three categories 0=36.1-38.9 °C, 1=36 °C or 39 °C and 2= 
(=>40 °C or <=35 °C) and BP was pre-coded into two categories of diastolic pressure 0 = 
>91 mmHg and 2=<90mmHg. This might have led to the wastage of their specificity. The 
variables should have been left as continuous and comparison of means by HIV status 
would have been attempted, despite the already mentioned differential missing.  
 
Information on NTS symptoms and rural-urban placement was not available in the dataset. 
The importance of symptoms was to detail the clinical presentation and the rural-urban 
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placement was to control for differential mortality, nevertheless controlling for provinces 
may have accommodated the rural-urban differential mortality.  
 
The use of a cross sectional design undermined the determination of sequence of events. 
Although it is known that invasive NTS is an HIV disease opportunistic infection, this 
study does not assert that HIV preceded NTS infection in the sequence of events. The 
study design did also not allow for elucidating the sequence of events with regard to TB or 
PCP exposing the lungs to NTS infection in HIV positive patients.  In addition, the 
collapse of immunosuppressive conditions into a single variable, while allowing for 
effective adjustment of confounding and effect modification, it caused the loss of 
specificity to conditions responsible for NTS in HIV negative patients. 
 
Despite these limitations, the study used data collected from almost all provinces in South 
Africa with most data (74%) coming from Gauteng province resulting in a larger sample 
size compared to previous studies.  It can be argued that a considerable number of patients 
in the Gauteng province could have come from other provinces by either referral or self-
referral and thus it is most unlikely that this affected the representativeness of other 
provinces. The larger sample size allowed for comparative analysis between HIV positive 
and negative patients by use of multivariate logistic regression and thus adjustment of 
confounders and effect modification was achieved resulting into eliciting the independent 
effect of HIV on mortality and clinical-microbiologic features.  
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CHAPTER 5 
5.0 CONCLUSION 
This study underscores the importance of HIV in patients with invasive NTS by 
quantifying its impact on clinical-microbiologic features and mortality. The study has 
shown that HIV infection is common among patients with invasive NTS and is associated 
with higher mortality, LRTI, fewer than 16 days of hospital stay, recurrent invasive NTS 
infection and Salmonella Typhimurium. It is important for clinicians to rule out HIV 
infection in patients with invasive NTS especially those presenting with LRTI and 
Salmonella Typhimurium infection in addition to recurrent NTS infection, which is a well 
known feature associated with HIV. 
 
5.1 RECOMMENDATIONS 
5.1.1 HIV prevention and management 
The excess mortality in HIV positive patients with invasive NTS calls for scaled up efforts 
in HIV prevention so that these deaths can be avoided. Due to HIV- NTS association, HIV 
testing and counselling should be offered routinely to patients with NTS with subsequent 
provision of HAART depending on results. 
5.1.2 TB and PCP 
Since TB or PCP could be antecedents for LRTI in HIV positive patients with invasive 
NTS, the two diseases should be actively investigated and managed in case of LRTI 
presentation, even in the absence of a suggestive clinical history. 
5.1.3 Treatment for invasive NTS 
The overall mortality of 32% and high frequency of recurrence in HIV positive patients is 
considerable notwithstanding antimicrobial use in these patients admitted to tertiary 
hospitals. Therefore, there is a need to revisit the first line treatment of invasive NTS 
especially to HIV positive patients. This can be achieved by investigating resistance 
 56 
patterns and conducting a clinical trial of newer and effective antimicrobials with long term 
effects, important for avoiding recurrence. 
 
5.1.4 Completeness of surveillance data 
Surveillance data is crucial for health planning. A mechanism for ensuring the 
completeness of information should be devised. This can be in form of incentives such as 
workshops and short term training on data management whereby the importance of 
complete data will be re-emphasized. 
Surveillance teams should also play their part by taking efforts to collect information such 
as CD4 count and viral load to allow for monitoring studies on the ARV roll out in the 
country. 
In addition there is a need to enhance the data collection tool for surveillance to include 
major symptoms and their duration that will be combined with complete data on GCS, 
temperature and cardiac arrest to allow for objective assessment of severity of NTS 
infection associated with HIV. 
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 APPENDICES 
Appendix I 
Surveillance sites 
Province Hospital 
Eastern Cape Umtata Provincial Hospital, Umtata,  
Free State Pelonomi Hospital and Universitas Hospital, Bloemfontein 
Gauteng o Chris Hani Baragwanath Hospital, Soweto 
o Johannesburg General Hospital, Johannesburg 
o GaRankuwa Hospital and Tswane, Pretoria 
Kwazulu 
Natal 
King Edward VIII Hospital, Durban, Addington and R K Khan 
Mpumalanga Rob Ferreira Hospital, Themba Hospital and Barberton Hospital, Nelspruit 
Limpopo  Polokwane-Mankweng Complex, Polokwane; Knobel; Standerton 
Western Cape Red Cross Hospital, Groote Schuur Hospital, Victoria Hospital and 
Tygerberg Hospital, Cape Town complex 
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